Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Kissei pays $33mm up front for rights to Rigel's Tavalisse

Executive Summary

Rigel Pharmaceuticals Inc. licensed Kissei Pharmaceutical Co. Ltd. exclusive rights to develop and sell its thrombocytopenia drug Tavalisse (fostamatinib disodium hexadydrate) in Japan, China, Taiwan, and the Republic of Korea.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies